About this item
Product details
Rezna (Resmetirom) 80 mg is a clinically proven, once-daily oral tablet and the first FDA-approved medication specifically designed to treat metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), in adults with moderate to advanced liver fibrosis. Manufactured by Nabiqasim, it offers a targeted therapeutic option for this progressive liver disease. FDA-Approved for MASH: The first and only oral medication approved to treat MASH with liver fibrosis. Dual Endpoint Efficacy: Clinically proven to achieve both MASH resolution (reduction of liver inflammation and ballooning) and significant reduction in liver fat. Addresses Fibrosis: Demonstrated benefit in slowing or stabilizing liver fibrosis progression, a key driver of long-term liver complications. Targeted Liver Action: As a thyroid hormone receptor-beta (THR-β) agonist, it works selectively in the liver to improve metabolic function and reduce harmful fat accumulation. Composition Each film coated tablet contains: Resmetirom: 80 mg Directions for Use As directed by the doctor.
- Medicines
- 14 Film Coated Tablets
- 1 variant
- Protected Dastak checkout
Know before you buy
Specifications
- Department
- Health
- Subcategory
- Medicines
- Brand
- Nabiqasim
- SKU
- 08964003525170
- Variant
- 14 Film Coated Tablets
- Tags
- Medicine, Resmetirom
- Condition
- New
Customer feedback
Ratings & reviews
For help with a purchase, open your orders or contact Dastak support.
